UPLIZNA 10 MG — DIN 02543931
INEBILIZUMAB : 10 MG · AMGEN CANADA INC · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is UPLIZNA?
UPLIZNA 10 MG contains INEBILIZUMAB : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02543931, held by AMGEN CANADA INC, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 31-Mar-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is UPLIZNA used for?
Monotherapy for adult Neuromyelitis Optica Spectrum Disorder (NMOSD) (AQP4-IgG seropositive) and treatment of adult Immunoglobulin G4-related disease (IgG4-RD) to reduce flare frequency.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Inebilizumab cost around the world?
Inebilizumab is listed on 5 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Czechia publishes a max producer price (ex-factory); Italy publishes a ex-factory (classe H); Norway publishes a max AUP (pharmacy retail). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United Arab Emirates | public | 1 | 1 | AED███.██ |
| Czechia | max producer price (ex-factory) | 1 | 1 | CZK███.██ |
| Italy | ex-factory (classe H) | 1 | 1 | EUR███.██ |
| Norway | max AUP (pharmacy retail) | 1 | 1 | NOK███.██ |
| Slovakia | categorised final price | 1 | 1 | EUR███.██ |
5 pack listings across 5 brand entries and 5 price bases, refreshed 07 Sep 2026. Ranges span every Inebilizumab pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 10 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | Carton containing three 100 mg/10 mL single-use vials. |
| Storage | Store prepared infusion solution for max 24 hours in refrigerator (2°C to 8°C) or 4 hours at room temperature (20°C to 25°C). Do not shake. |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Cold chain. This product is stored refrigerated. Nexara ships it on a validated cold chain with temperature monitoring; a delivery address that cannot receive and store it at 2–8 °C on arrival must be flagged before the order is placed.
Substance and classification
| Active substance | Inebilizumab |
|---|---|
| ATC code | L04AG10 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02543931 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2543931 |
| Brand name | UPLIZNA |
| Generic / active ingredient | INEBILIZUMAB : 10 MG |
| Market authorization holder | AMGEN CANADA INC |
| Health Canada schedule | Schedule D |
| ATC code | L04AG10 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L04AG |
| Current status | MARKETED |
| Status date | 31-Mar-2025 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Initial: 300 mg IV infusion, followed 2 weeks later by 300 mg. Subsequent: 300 mg IV every 6 months. Administer over ~90 mins with premedication (corticosteroid, antihistamine, antipyretic).
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity; life-threatening infusion reaction to UPLIZNA; severe active infection (e.g., HBV); active/untreated latent TB; history of PML; severely immunocompromised; active malignancy.
Warnings and precautions
Risk of infusion reactions (including anaphylaxis), infections, late-onset neutropenia, HBV reactivation, PML, and reduction in immunoglobulins. Evaluate for TB before initiation.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
2 · Same class — other molecules in ATC L04AG
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Belimumab | BENLYSTA | 4 | 3 | Yes |
| Vedolizumab | ENTYVIO | 3 | 3 | Yes |
| Alemtuzumab | LEMTRADA · MABCAMPATH | 3 | 2 | Yes |
| Ofatumumab | KESIMPTA | 2 | 1 | Yes |
| Inebilizumab | UPLIZNA | 1 | 1 | Yes |
| Natalizumab | TYSABRI | 1 | 1 | Yes |
| Ocrelizumab | OCREVUS | 1 | 1 | Yes |
| Anifrolumab | SAPHNELO | 1 | 1 | Yes |
| Rozanolixizumab | RYSTIGGO | 1 | 1 | Yes |
| Teprotumumab | TEPEZZA | 1 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC L04A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| L04AX | Azathioprine · Dimethyl Fumarate · Lenalidomide · Methotrexate · Other Immunosuppressants · +3 more | 191 | 124 |
| L04AC | Anakinra · Basiliximab · Bimekizumab · Brodalumab · Canakinumab · +13 more | 85 | 75 |
| L04AB | Adalimumab · Certolizumab Pegol · Etanercept · Golimumab · Infliximab | 71 | 55 |
| L04AA | Abatacept · Alefacept · Antilymphocyte Immunoglobulin (Horse) · Antithymocyte Immunoglobulin (Rabbit) · Apremilast · +4 more | 73 | 42 |
| L04AD | Ciclosporin · Tacrolimus | 49 | 30 |
| L04AK | Leflunomide · Teriflunomide | 44 | 25 |
| L04AH | Everolimus · Sirolimus | 36 | 23 |
| L04AF | Baricitinib · Deucravacitinib · Ritlecitinib · Tofacitinib · Upadacitinib | 23 | 19 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.